Celcuity Q4 Earnings Call Highlights [Yahoo! Finance]
Celcuity Inc. (CELC)
Last celcuity inc. earnings: 3/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
celcuity.com/home/investors
Company Research
Source: Yahoo! Finance
Celcuity (NASDAQ:CELC) executives used the company's fourth-quarter and full-year 2025 earnings call to highlight progress toward a potential 2026 U.S. launch of gedatolisib, review data from its lead breast cancer program, and outline its commercial and regulatory preparations. Management also reported higher operating expenses and a larger net loss in 2025 as the company expanded headcount and ramped launch-related activities. Gedatolisib NDA accepted with priority review Chief Executive Officer and co-founder Brian Sullivan said the company is preparing for what it expects could be a “transformative year” as it moves toward a potential approval and commercialization of gedatolisib. Sullivan said the FDA has accepted Celcuity's new drug application (NDA) and granted priority review, with a Prescription Drug User Fee Act (PDUFA) goal date of July 17, 2026 . He added that the submission was made under the FDA's Real-Time Oncology Review Program , which he described as being used
Show less
Read more
Impact Snapshot
Event Time:
CELC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CELC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CELC alerts
High impacting Celcuity Inc. news events
Weekly update
A roundup of the hottest topics
CELC
News
- Celcuity (CELC) had its price target raised by Stifel Nicolaus from $115.00 to $125.00. They now have a "buy" rating on the stock.MarketBeat
- Celcuity (CELC) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $122.00 price target on the stock.MarketBeat
- Celcuity Inc (CELC) Q4 2025 Earnings Call Highlights: Navigating Losses Amidst Promising Drug ... [Yahoo! Finance]Yahoo! Finance
- Celcuity Inc. (CELC) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Celcuity outlines potential $2.5B annual peak revenue for gedatolisib amid pivotal clinical milestones and commercial launch preparations [Seeking Alpha]Seeking Alpha
CELC
Earnings
- 3/25/26 - Beat
CELC
Sec Filings
- 3/26/26 - Form 10-K
- 3/25/26 - Form 8-K
- 3/24/26 - Form SCHEDULE
- CELC's page on the SEC website